Helicobacter pylori Vaccine Effective in Chinese Children

An immunogenic and safe oral recombinant vaccine prevented 72% of infections during the first year after vaccination.

Helicobacter pylori is associated with gastritis, ulceration, and malignancy. Previous attempts to develop an effective vaccine against the bacterium have been unsuccessful. Investigators now report results of an industry-funded, single-center, phase III, randomized trial in China of an oral recombinant H. pylori vaccine using urease B subunit fused with heat-labile enterotoxin B subunit (derived from Escherichia coli).

In 2004 and 2005, 4464 healthy children (aged 6–15 years) without history of H. pylori infection were randomly assigned to receive the vaccine or placebo (vaccine excipients) on days 0, 14, and 28 after a 2-hour fast and ingestion of a buffer solution.

At 1 year after vaccination, fewer H. pylori infections had occurred in the…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Helicobacter pylori Vaccine Effective in Chinese Children

Topics

Reviewing Author